Hemab Aps
Clinical trials sponsored by Hemab Aps, explained in plain language.
-
New hope for rare bleeding disorder: sutacimig trial launches
Disease control Recruiting nowThis study is testing a new drug called sutacimig in 18 adults with congenital factor VII deficiency, a rare condition that causes severe bleeding. The goal is to see if a single dose of the drug is safe and helps control bleeding. Participants will be monitored for side effects …
Phase: PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated May 17, 2026 08:03 UTC
-
New hope for bleeding disorder: experimental drug HMB-002 enters human trials
Disease control Recruiting nowThis study tests a new medicine, HMB-002, for people with Von Willebrand disease (types 1 and 2), a bleeding disorder. The trial has two parts: first, a single dose to check safety and how the drug works in the body; second, repeated doses to see if it helps control bleeding. Abo…
Phase: PHASE1, PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New study aims to map Real-World bleeding in von willebrand disease
Knowledge-focused Recruiting nowThis study is gathering information about bleeding episodes, quality of life, and treatment use in 200 people with von Willebrand disease (VWD). Participants will report their bleeding events and complete surveys over time. The data will help researchers understand the daily impa…
Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC